

(510006)

SuValue® 2016 1 1 2020 12 31

1 1

858

 $P > 0.05$ $P < 0.01$

Effectiveness of haemocoagulase agkistrodon *versus* tranexamic acid and sodium chloride in the prevention and treatment of perioperative bleeding: a real-world study

Health Economic Research Institute, School of Pharmaceutical Sciences, SunYat sen University, Guangzhou 510006, P. R. China

Corresponding author: XUAN Jianwei, Email: xuanjw3@mail.sysu.edu.cn

Abstract Objective To compare the effectiveness of haemocoagulase agkistrodon and tranexamic acid and sodium chloride in the prevention and treatment of perioperative bleeding in a real world setting. **Methods** A research database was constructed based on the records of inpatient visits using haemocoagulase agkistrodon and tranexamic acid and sodium chloride according to the SuValue® database from January 1, 2016 to December 31, 2020. The patients were divided into two groups according to the different interventions. After matching with a 1:1 propensity score, the effectiveness of two groups was compared. **Results** A total of 858 patients were included in each of the two groups, and there was no statistically significant difference in baseline characteristics between the two groups ($P > 0.05$). Research results showed that patients using haemocoagulase agkistrodon had significantly reduced length of hospital stay, decrease in hematocrit, average estimated surgical bleeding, and decrease in hemoglobin ($P < 0.01$). **Conclusion** Haemocoagulase agkistrodon has better effectiveness than tranexamic acid and sodium chloride for reducing perioperative blood loss based on current real world evidence.

Key words Real world study; Propensity score matching; Haemocoagulase agkistrodon; Tranexamic acid and sodium chloride; Perioperative bleeding; Effectiveness

[1]

[3-4]

[2]

[5-6]



										1																																																																																													
										<table><tr><th colspan="2">n 858</th><th colspan="2">n 858</th><th>t/χ^2</th><th>P</th></tr><tr><td rowspan="2">[8]</td><td rowspan="2">%</td><td>48.90</td><td>14.89</td><td>48.77</td><td>17.36</td><td>0.49</td><td>0.689</td></tr><tr><td>563</td><td>65.62</td><td>563</td><td>65.62</td><td>0</td><td>1.000</td></tr><tr><td rowspan="2">[9]</td><td rowspan="2">%</td><td>295</td><td>34.38</td><td>295</td><td>34.38</td><td></td><td></td></tr><tr><td>604</td><td>70.40</td><td>624</td><td>72.73</td><td>1.03</td><td>0.309</td></tr><tr><td rowspan="2">[10]</td><td rowspan="34">%</td><td>254</td><td>29.60</td><td>234</td><td>27.27</td><td></td><td></td></tr><tr><td>0</td><td>0.00)</td><td>0</td><td>0.00</td><td>1.24</td><td>0.265</td></tr><tr><td colspan="2">4 0.47</td><td colspan="2">9 1.05</td><td></td><td></td></tr><tr><td colspan="2">854 99.53</td><td colspan="2">849 98.95</td><td></td><td></td></tr><tr><td colspan="2">PT</td><td colspan="2">11.41 1.41</td><td colspan="2">11.42 2.16</td><td>-1.41</td><td>0.079</td></tr><tr><td colspan="2">APTT</td><td colspan="2">28.93 6.08</td><td colspan="2">28.92 5.07</td><td>1.10</td><td>0.136</td></tr><tr><td colspan="2">TT</td><td colspan="2">17.70 1.97</td><td colspan="2">17.61 1.92</td><td>2.26</td><td>0.988</td></tr><tr><td colspan="2">FIB g/L</td><td colspan="2">3.00 1.01</td><td colspan="2">3.04 1.01</td><td>-0.005</td><td>0.502</td></tr></table>		n 858		n 858		t/ χ^2	P	[8]	%	48.90	14.89	48.77	17.36	0.49	0.689	563	65.62	563	65.62	0	1.000	[9]	%	295	34.38	295	34.38			604	70.40	624	72.73	1.03	0.309	[10]	%	254	29.60	234	27.27			0	0.00)	0	0.00	1.24	0.265	4 0.47		9 1.05				854 99.53		849 98.95				PT		11.41 1.41		11.42 2.16		-1.41	0.079	APTT		28.93 6.08		28.92 5.07		1.10	0.136	TT		17.70 1.97		17.61 1.92		2.26	0.988	FIB g/L		3.00 1.01		3.04 1.01		-0.005	0.502
n 858		n 858		t/ χ^2	P																																																																																																		
[8]	%	48.90	14.89	48.77	17.36	0.49	0.689																																																																																																
		563	65.62	563	65.62	0	1.000																																																																																																
[9]	%	295	34.38	295	34.38																																																																																																		
		604	70.40	624	72.73	1.03	0.309																																																																																																
[10]	%	254	29.60	234	27.27																																																																																																		
		0	0.00)	0	0.00	1.24	0.265																																																																																																
4 0.47		9 1.05																																																																																																					
854 99.53		849 98.95																																																																																																					
PT		11.41 1.41		11.42 2.16		-1.41	0.079																																																																																																
APTT		28.93 6.08		28.92 5.07		1.10	0.136																																																																																																
TT		17.70 1.97		17.61 1.92		2.26	0.988																																																																																																
FIB g/L		3.00 1.01		3.04 1.01		-0.005	0.502																																																																																																
										PT	APTT	TT																																																																																											
										FIB																																																																																													
										k_2 0.033 08 k_3 0.183 3																																																																																													
										R 3.5.3																																																																																													
										propensity score matching																																																																																													
										PSM																																																																																													
										4																																																																																													
										Wilcoxon																																																																																													
										t $P<0.05$																																																																																													
										2																																																																																													
										2.1																																																																																													
										51 549																																																																																													
										16 387																																																																																													
										35 182																																																																																													
										1 859																																																																																													
										3 781																																																																																													
										1 1																																																																																													
										858																																																																																													
										2.2																																																																																													
										1																																																																																													
										4																																																																																													
										$P>0.05$																																																																																													
										2.3																																																																																													
										Hct																																																																																													
										HB																																																																																													
										eTBL																																																																																													

1

1.1

220

34

2016

1

1

2020

12

31

46

140

SuValue®

hematocrit

HB

loss

eTBL

volume

PBV

Hct

Hct_{post}

Hct

Hct_{post}

Hct

PBV

k_1

k_2

k_3

0.366

9

k_2

0.032

19

k_3

0.604

1

hemoglobin

estimated total blood

patient blood

eTBL

PBV

Hct_{pre}

Hct_{pre}

k_1

k_2

k_3

0.356

1

[11 15]

[16]

[17]

[18]

[8]

2

- 1 . , 2018, 24(27): 3252 3258.
- 2 — , 2017, 10(1): 1 7.
- 3 . , 2016, 22(21): 4345 4347.
- 4 Borghi B, Borghi R. Blood saving techniques. [Transplant Proc](#), 2011, 43(1): 333 337.
- 5 Koh MB, Hunt BJ. The management of perioperative bleeding. [Blood Rev](#), 2003, 17(3): 179 185.

Kozek Langenecker SA, Afshari A, Albaladejo P, *et al*.
Management of severe perioperative bleeding: Guidelines from the
European society of anaesthesiology. [Eur J Anaesthesiol](#) ū

[30]

- 18 Gao F, Li Z, Zhang K, *et al.* Four methods for calculating blood loss after total knee arthroplasty. *Chin Med J*, 2015, 128(21): 2856 2860.
- 19 , 2005, 18(2): 121 123.
- 20 , 2013, 39(1): 16 17.
- 21 , 2014, 23(5): 81 82.
- 22 , 2021, 40(9): 1228 1231.
- 23 Ghadimi K, Levy JH, Welsby IJ. Perioperative management of the bleeding patient. *Br J Anaesth*, 2016, 117(suppl 3): iii18 iii30.
- 24 Devereaux PJ, Marcucci M, Painter TW, *et al.* Tranexamic acid in patients undergoing noncardiac surgery. *N Engl J Med*, 2022, 386(21): 1986 1997.
- 25 Colomina MJ, Contreras L, Guilabert P, *et al.* Clinical use of tranexamic acid: evidences and controversies. *Braz J Anesthesiol*, 2022, 72(6): 795 812.
- 26 , 2008, 26(1): 2 4, 91.
- 27 Murao S, Nakata H, Roberts I, *et al.* Effect of tranexamic acid on thrombotic events and seizures in bleeding patients: a systematic review and meta analysis. *Crit Care*, 2021, 25(1): 380.
- 28 , 2015, 18(5): 617 619.
- 29 , 2012, 31(10): 1321 1324.
- 30 , 2020, 36(3): 346 350.

2022-09-20

2023-03-28